Effectiveness and safety of morphine sulfate extended-release capsules in patients with chronic, moderate-to-severe pain in a primary care setting
James Brown1, Beatrice Setnik2, Keung Lee3, Jody M Cleveland2, Carl L Roland2, Linda Wase4, Lynn Webster5 1Jena Medical, Ormond Beach, FL; 2Pfizer Inc, Cary, NC; 3Randolph Medical Associates, Asheboro, NC; 4Archimedes Pharma US Inc, Bedminster, NJ; 5Lifetree Clinical Research, Salt Lake City, UT, USA Background: The purpose of this study was to determine the effectiveness and safety of morphine sulfate extended-release capsules among primary care patients with chronic, moderate-to-severe pain using a universal precautions approach that assessed and monitored risk for opioid misuse and abuse. Methods: This open-label, uncontrolled, multicenter, prospective study was conducted in primary care centers (n = 281) and included opioid-naïve and opioid-experienced patients with either a pain score ≥4 (0 = no pain, 10 = pain as bad as you can imagine), or with unacceptable side effects while taking opioids. The patients were treated with morphine sulfate extended-release capsules for up to four months. Patient-rated pain intensity (worst, least, average) over the past 24 hours (0–10 scale), pain interference with seven activities of daily living (0 = no interference, 10 = completely interferes), and adverse events were recorded. Results: Of 1487 patients who filled at least one prescription, 561 (38%) completed the study. Patients were primarily white (87%) and female (57%); 92% had pain for more than one year; and 79% were opioid-experienced. Median age was 52 years. Decreases in mean (+- standard deviation) average pain scores (baseline 6.2 +- 2.3) were -0.8 +- 2.2 at visit 2 (5–14 days later), and -1.6 +- 2.3 and -1.7 +- 2.2 at visits 3 and 4 (spaced 3–4 weeks apart), respectively, and -1.1 +- 2.4 at visit 5 (included patients withdrawn from the study who were no longer taking the study drug). A similar trend was observed for worst pain and least pain scores and for pain interference with activities. Fifty-one percent of the safety population patients and 81% in the completer population reported being satisfied or very satisfied with the study treatment. Most common adverse events were typical of opioids, ie, constipation (14%), nausea (11%), vomiting (5%), and somnolence (5%). Conclusion: The results suggest that pain outcomes improved in patients with chronic, moderate-to-severe pain receiving morphine sulfate extended-release capsules within the context of a structured universal precautions approach in the primary care setting. Keywords: opioids, analgesics, primary care, pain assessment, substance abuse, universal precautions.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2011 |
---|---|
Erschienen: |
2011 |
Enthalten in: |
Zur Gesamtaufnahme - year:2011 |
---|---|
Enthalten in: |
Journal of Pain Research - (2011), default, Seite 373-384 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Brown J [VerfasserIn] |
---|
Links: |
doaj.org [kostenfrei] |
---|
Themen: |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
DOAJ071105999 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ071105999 | ||
003 | DE-627 | ||
005 | 20230502132920.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2011 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ071105999 | ||
035 | |a (DE-599)DOAJ8aeb8be77fe4482eaaba821203e7a9fe | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a R5-920 | |
100 | 0 | |a Brown J |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effectiveness and safety of morphine sulfate extended-release capsules in patients with chronic, moderate-to-severe pain in a primary care setting |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a James Brown1, Beatrice Setnik2, Keung Lee3, Jody M Cleveland2, Carl L Roland2, Linda Wase4, Lynn Webster5 1Jena Medical, Ormond Beach, FL; 2Pfizer Inc, Cary, NC; 3Randolph Medical Associates, Asheboro, NC; 4Archimedes Pharma US Inc, Bedminster, NJ; 5Lifetree Clinical Research, Salt Lake City, UT, USA Background: The purpose of this study was to determine the effectiveness and safety of morphine sulfate extended-release capsules among primary care patients with chronic, moderate-to-severe pain using a universal precautions approach that assessed and monitored risk for opioid misuse and abuse. Methods: This open-label, uncontrolled, multicenter, prospective study was conducted in primary care centers (n = 281) and included opioid-naïve and opioid-experienced patients with either a pain score ≥4 (0 = no pain, 10 = pain as bad as you can imagine), or with unacceptable side effects while taking opioids. The patients were treated with morphine sulfate extended-release capsules for up to four months. Patient-rated pain intensity (worst, least, average) over the past 24 hours (0–10 scale), pain interference with seven activities of daily living (0 = no interference, 10 = completely interferes), and adverse events were recorded. Results: Of 1487 patients who filled at least one prescription, 561 (38%) completed the study. Patients were primarily white (87%) and female (57%); 92% had pain for more than one year; and 79% were opioid-experienced. Median age was 52 years. Decreases in mean (+- standard deviation) average pain scores (baseline 6.2 +- 2.3) were -0.8 +- 2.2 at visit 2 (5–14 days later), and -1.6 +- 2.3 and -1.7 +- 2.2 at visits 3 and 4 (spaced 3–4 weeks apart), respectively, and -1.1 +- 2.4 at visit 5 (included patients withdrawn from the study who were no longer taking the study drug). A similar trend was observed for worst pain and least pain scores and for pain interference with activities. Fifty-one percent of the safety population patients and 81% in the completer population reported being satisfied or very satisfied with the study treatment. Most common adverse events were typical of opioids, ie, constipation (14%), nausea (11%), vomiting (5%), and somnolence (5%). Conclusion: The results suggest that pain outcomes improved in patients with chronic, moderate-to-severe pain receiving morphine sulfate extended-release capsules within the context of a structured universal precautions approach in the primary care setting. Keywords: opioids, analgesics, primary care, pain assessment, substance abuse, universal precautions | ||
653 | 0 | |a Medicine (General) | |
700 | 0 | |a Setnik B |e verfasserin |4 aut | |
700 | 0 | |a Lee K |e verfasserin |4 aut | |
700 | 0 | |a Clevel |e verfasserin |4 aut | |
700 | 0 | |a JM |e verfasserin |4 aut | |
700 | 0 | |a Rol |e verfasserin |4 aut | |
700 | 0 | |a CL |e verfasserin |4 aut | |
700 | 0 | |a Wase L |e verfasserin |4 aut | |
700 | 0 | |a Webster L |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Journal of Pain Research |d Dove Medical Press, 2009 |g (2011), default, Seite 373-384 |w (DE-627)DOAJ000111899 |x 11787090 |7 nnns |
773 | 1 | 8 | |g year:2011 |g number:default |g pages:373-384 |
856 | 4 | 0 | |u https://doaj.org/article/8aeb8be77fe4482eaaba821203e7a9fe |z kostenfrei |
856 | 4 | 0 | |u http://www.dovepress.com/effectiveness-and-safety-of-morphine-sulfate-extended-release-capsules-a8617 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1178-7090 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2011 |e default |h 373-384 |